EDUCATION

 

Mi-mAbs, a privileged partner of the Aix-Marseille University Master for Immunology program

One of the missions of Mi-mAbs is to contribute to immunotechnology training of Aix-Marseille University students, notably in all areas related to the use of monoclonal antibodies for research, diagnosis and therapeutics. As such, a Professor of immunology who participates in the formation of the Master students heads Mi-mAbs.


Marseille has a long tradition of excellence in the field of Immunology teaching, with world-renowned research centers in this specialty (CIML and CRCM), allowing many students to graduate from Licence, Master and PhD programs in the field.

Two Master programs (research and master pro) offer solid foundations in basic and applied Immunology to students with international background who can then pursue a career with a PhD in Immunology or an engineer’s diploma in Immunotechnology.

These courses are at the heart of two scientific, technological and medical revolutions: monoclonal antibodies and immunotherapy. Today, monoclonal antibodies are the major class of drugs in oncology (monoclonal antibodies alone generate an average turnover of EUR 50 billion per year) but they are also part of new immunotherapies that have revolutionized the treatment of cancers (see the therapeutic benefits of anti-CTLA4 and anti-PD1immuno-modulatory antibodies) and inflammatory diseases. Analysts estimate that the market of only of antibodies known as immuno-modulators should quickly reach 30 $ billion annually (source CITI research 2013). These developments, together with other immunological tools for research and diagnostic, lead to a renewed need of Ingeneers and PhDs mastering basic and applied immunology, with specific knowledge in the monoclonal antibody field.

Marseille, is at the forefront of this revolution as one of the most promising candidates (anti-KIR/LIRILUMAB) antibodies are the fruit of collaboration between the CIML, Innate Pharma, and the CRCM/IPC. Now in clinical trials in different cancers, this success symbolizes in itself the strength of the continuum "basic, translational, industrial and clinical immunology" and the ambition of the new Marseille Immunopole (MI) cluster.

So MI-mABs and its large contribution to the Immunotechnology teaching program is a keystone of the ambitous  project which make MI a leading place for immunotherapy antibodies and the site of one of the best schools of immunology in the world.

These courses are at the heart of two scientific, technological and medical revolutions: monoclonal antibodies and immunotherapy. Today, monoclonal antibodies are the major class of drugs in oncology (monoclonal antibodies alone generate an average turnover of EUR 50 billion per year1) but they are also part of new immunotherapies that have revolutionized the treatment of cancers (see the therapeutic benefits of anti-CTLA4 and anti-PD1immuno-modulatory antibodies) and inflammatory diseases. Analysts estimate that the market of only of antibodies known as immuno-modulators should quickly reach 30 $ billion annually2. These developments, together with other immunological tools for research and diagnostic, lead to a renewed need of Ingeneers and PhDs mastering basic and applied immunology, with specific knowledge in the monoclonal antibody field.

Marseille, is at the forefront of this revolution as one of the most promising candidates (anti-KIR/LIRILUMAB) antibodies are the fruit of collaboration between the CIML, Innate Pharma, and the CRCM/IPC. Now in clinical trials in different cancers, this success symbolizes in itself the strength of the continuum "basic, translational, industrial and clinical immunology" and the ambition of the new Marseille Immunopole (MI) cluster.

So MI-mABs and its large contribution to the Immunotechnology teaching program is a keystone of the ambitous  project which make MI a leading place for immunotherapy antibodies and the site of one of the best schools of immunology in the world.

1 Datamonitor 2011 Antibody Market
2 CITI Research 2013 & Datamonitor 2013 Immuno-oncology Market